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Comparison of the Impact of Annual and Semiannual Mass Drug Administration on Lymphatic
Filariasis Prevalence in Flores Island, Indonesia
Taniawati Supali,1 Yenny Djuardi,1 Adriani Lomiga,2 Sovie Nur Linda,1 Elisa Iskandar,1 Charles W. Goss,3 John Philip Miller,3
Gary J. Weil,4 and Peter U. Fischer4*
1

Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; 2Program Studi Ilmu Kesehatan Masyarakat, Program
Pascasarjana, Universitas Nusa Cendana, Kupang, Indonesia; 3Division of Biostatistics, Washington University School of Medicine, St. Louis,
Missouri; 4Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri

Abstract. We compared the impact of annual and semiannual mass drug administration (MDA) on the prevalence of
Brugia timori and Wuchereria bancrofti in Flores Island. Two villages (Paga, B. timori only; Lewomada, co-endemic)
received annual MDA with diethylcarbamazine/albendazole and a larger village (Pruda, co-endemic) received semiannual
MDA. Infection parameters (microﬁlariae [Mf], antibodies to recombinant ﬁlarial antigen BmR1 [Brugia Rapid (BR)], and a
test for W. bancrofti antigenemia [immunochromatographic test (ICT)]) were assessed before and after treatment. The
crude Mf prevalence in Pruda decreased after ﬁve semiannual treatments from 14.2% to 1.2%, whereas the Mf prevalence
in the other two villages decreased after three annual treatments from 3.9% to 0% and from 5% to 0.3%, respectively. ICT
positivity prevalence in Pruda and Lewomada decreased from 22.9% and 6.5% to 7% and 0.8%, respectively, whereas
BR antibody prevalence in Pruda, Lewomada, and Paga decreased from 28.9%, 31.7%, and 12.5% to 3.6%, 4.1%, and
1.8%, respectively. Logistic regression analysis indicated that that Mf, BR, and ICT prevalence decreased signiﬁcantly over
time and that for the Mf and ICT outcomes the semiannual treatment had higher odds of positivity. Model-adjusted
prevalence estimates revealed that apparent differences in treatment effectiveness were driven by differences in baseline
prevalence and that adjusted prevalence declined more rapidly in the semiannual treatment group. We conclude that in this
setting, annual MDA was sufﬁcient to reduce Mf prevalence to less than 1% in areas with low to moderate baseline
prevalence. Semiannual MDA was useful for rapidly reducing Mf prevalence in an area with higher baseline endemicity.

INTRODUCTION

effective strategies to accelerate LF elimination are highly
desirable.
Previous modeling studies based on data from Ghana and
India predicted that semiannual MDA would signiﬁcantly
speed up LF elimination and reduce the overall cost of MDA
programs by 11–18%.6 To test this hypothesis for Indonesia,
we compared the impact of annual and semiannual MDA with

Lymphatic ﬁlariasis (LF) is a common neglected tropical
disease in Indonesia that may hinder economic development.1
The country committed to the Global Program to Eliminate
Lymphatic Filariasis (GPELF) in the year 2002, but progress
has been slow and variable. The national LF elimination program is based on annual mass drug administration (MDA)
using a single dose of diethylcarbamazine (DEC) combined
with albendazole (ALB) in all areas with microﬁlaremia (Mf) or
antigen (Wuchereria bancrofti) prevalence of 1% or higher. In
2016, it was estimated that a population of about 62 million still
required MDA for LF elimination. Indonesia’s population at risk
ranks third in the world, behind only India and Nigeria.2
The epidemiology of LF in Indonesia is unique because it is
caused by three different ﬁlarial species, namely W. bancrofti,
Brugia malayi, and Brugia timori. Furthermore, W. bancrofti
and B. malayi each have several distinct ecotypes with different vector species and ecology. This variability leads to
varied transmission dynamics and responses to intervention.3
Brugia timori is endemic in eastern Indonesia (east of the
Wallace line). Wuchereria bancrofti is sometimes co-endemic
with B. timori, but it is usually transmitted by sympatric but
different anopheline vector species. Previous studies by our
group have shown that annual MDA can be efﬁciently performed in eastern Indonesia and provided evidence that
LF caused by B. timori and W. bancrofti can be locally
eliminated.4,5 Unfortunately, only 48 of the 235 evaluation
units in Indonesia have passed transmission assessment
surveys (TAS) and stopped MDA, whereas 80% of the
implementation units still require MDA.2 Therefore, cost* Address correspondence to Peter U. Fischer, Washington University
School of Medicine, 4444 Forest Park Blvd., St. Louis, MO 63108.
E-mail: puﬁscher@wustl.edu

FIGURE 1. Map of Indonesia and Flores Island showing the study
sites in Sikka district. Pruda received semiannual mass drug administration (MDA), whereas Lewomada and Paga received annual MDA.
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TABLE 1
Examined study population in the three sentinel study areas in Sikka district, province Nusa Tenggara Timur, Indonesia
Paga

Pre-mass drug administration
Year 1
Year 2
Year 3

Lewomada

Pruda

Total

Males (%)

Total

Males (%)

Total

Males (%)

Total

Males (%)

Total

546 (37.8)
392 (39.4)
426 (38.2)
358 (39.6)

1,443
994
1,114
905

311 (43.1)
360 (42.6)
382 (44.5)
400 (45.9)

722
846
858
871

488 (47.2)
475 (47.1)
500 (47.9)
437 (42.5)

1,033
1,007
1,043
1,028

1,345 (42.1)
1,227 (43.1)
1,308 (43.4)
1,195 (42.6)

3,198
2,847
3,015
2,804

DEC and ALB on ﬁlarial infection parameters in selected areas
of Flores Island where B. timori and W. bancrofti are endemic.
We found that both treatment regimens were effective for
dramatically reducing infection markers with no marked
advantage of twice-yearly MDA.
METHODS
Ethical approval and selection of the study area. The
study received ethical approval from the Ethics Committee of
Faculty of Medicine, University of Indonesia (No.61/PT02.FK/
ETIK/2011). This study was registered at ClinicalTrials.gov
with identiﬁer No NCT01905423.
The study was initiated in 2011 with screening surveys to
identify and select LF-endemic villages in Sikka, Flores Timur,
and Lembata districts in the province East Nusa Tenggara
Timur. In these surveys Mf were detected by thick night blood
smears. In Flores Timur, a convenience sample of 2,584
subjects residing in 24 villages was tested and eight villages
were Mf positive with crude prevalence between 1% and 16%.
One village was co-endemic for B. timori and W. bancrofti,
whereas all other villages were endemic for W. bancrofti only.
In Lembata, we screened 653 subjects from seven villages,
and only nine W. bancrofti Mf-positive individuals were identiﬁed in a single village. In Sikka district, 2,341 subjects from 17
villages were tested for Mf, and 16 villages were positive for
B. timori with crude Mf prevalence of 1–22%. In addition, three
villages were co-endemic for W. bancrofti. Because we wanted to focus on brugian ﬁlariasis, we selected three villages in
Sikka district for our study.
Study area and population. Sikka district (population approximately 300,000 in 2010) is located on Flores Island
(Figure 1). The district comprises 21 sub-districts with 147
villages that are served by 22 primary health centers (Puskesmas). With the exception of the district capital Maumere,
most areas are rural and often served only by dirt roads or boat
(http://www.sikkakab.go.id). The study village Paga is in the
southwestern part of Sikka, whereas Pruda and Lewomada
are in the more remote eastern part of the district (Figure 1).
Four cross-sectional ﬁeld surveys were performed in the
study villages, at baseline before MDA and at 12 months,
24 months, and 36 months after the initial MDA. During the
survey, all eligible individuals aged 5 years and older who
consented to the study provided demographic information
(gender, age, and bed net use) and were tested for Mf, antiﬁlarial antibodies, and circulating ﬁlarial antigen. Individuals
who were not eligible for MDA or who moved to the village
within the last year were not included in the study. Individuals
who did not consent to the survey but were eligible and consenting with MDA were offered MDA participation only.
Treatment. Three villages were assigned to two MDA
groups. The ﬁrst group (Paga and Lewomada) received annual

treatment with DEC (6 mg/kg) combined with ALB (400 mg)
and Pruda village received twice-yearly treatment with DEC/
ALB. The distribution of DEC/ALB was performed in collaboration with the health authority of the local government and the
Puskesmas. The ﬁrst rounds of MDA were distributed to all
eligible residents in Paga and Pruda in March 2011 and in
Lewomada in March 2012. Annual MDA was provided every
12 months, whereas Pruda received additional treatments at
month 6 and 18 after the ﬁrst treatment. Thus, Paga and
Lewomada received a total of three rounds of MDA over a
period of 24 months, whereas Pruda received ﬁve rounds.
Reexaminations were performed annually, and the last survey
was performed 36 months after the ﬁrst treatment (12 months
after the last round of MDA). The last surveys were performed
in March 2014, in two study villages (Paga and Pruda), and in
March 2015 (Lewomada).
Detection of Mf by microscopy. A total of 250 μL of ﬁnger
blood was collected at night (between 8 and 11 PM) in an
ethylenediaminetetraacetic acid (EDTA)-coated tube. Sixty
microliters of blood was evenly spread in three lines onto a
clean glass slide labeled with unique barcode for each participant, dried for 2 days, de-hemoglobinized for 3 minutes,
air-dried, ﬁxed with methanol for 1 minute, and stained with
Giemsa (1:14) for 15 minutes. The stained slides were examined under the microscope for the presence of Mf. The result
from each slide was entered into a cellular phone and linked to
the participant’s barcode with a barcode reader. The remaining
blood samples were centrifuged, plasma was separated for
later immunoglobulin G4 (IgG4) antibody or antigen detection,
and stored at −20°C. Plasma samples were transported with ice
packs to the laboratory of the Department of Parasitology in
Jakarta and stored at −20°C until use.
Detection of antiﬁlarial antibodies and circulating
ﬁlarial antigen. Speciﬁc antiﬁlarial IgG4 antibodies reactive to
the recombinant B. malayi antigen BmR1 were detected using
the Brugia Rapid test (BR) (Reszon Sdn Bhd, Bangi, Malaysia).
The test was performed using 25 μL of plasma according to the
recommendation of the manufacturer.5 Circulating W. bancrofti
antigen was detected with the Binax Now® Filariasis Test (ICT)
(Alere, Scarborough, ME) with stored plasma according to the
protocol provided by the manufacturer. The result was read
strictly at 10 minutes after application of the sample.
Data management and analysis. All data were recorded
and synchronized in a Motorola cellular phone (XT 720;
Motorola, Chicago, IL) before being sent to the server using
the LinksSystem.7 For analysis, the data were downloaded as
Excel ﬁles from the server and transferred into SPSS version
20 (Armonk, NY) or SAS version 9.4 (Cary, NC). The data before and after treatment were regarded as independent data,
so unpaired statistical tests were used. The unadjusted Mf
prevalence and antibody and antigen prevalence in each village before and after treatment were compared and analyzed

338

SUPALI AND OTHERS

TABLE 2
Compliance with MDA in the study population (aged 5 years and older)
in the three sentinel study areas in Sikka district
Paga

Year 1
Year 2
Year 3

Lewomada

Pruda

Total

N

%

N

%

N

%

N

%

735
781
731

73.9
70.1
80.8

683
614
648

80.7
71.6
74.4

817
847
922

81.1
81.2
89.8

2,235
2,242
2,301

78.5
74.4
82.1

MDA = mass drug administration. Participants were asked during the survey whether they
participated in any lymphatic ﬁlariasis MDA in the previous year.

using a chi-square test. Changes in infection prevalence of
ﬁlarial infections were assessed by Fisher’s exact test. The
geometric mean of Mf density was calculated with data from
persons with microﬁlaremia. The Mf, ICT, and BR outcomes
were later analyzed using a logistic regression analysis;
neighborhood nested within village was treated as a random
effect to account for correlation among subjects within a
neighborhood (PROC GLIMMIX, SAS 9.4). In this analysis, we
assessed the treatment regimen, time, and their interaction.
The interaction term was retained if it was signiﬁcant (P < 0.05),
otherwise it was removed from the model. The ﬁnal model
for each outcome was also used to obtain model-adjusted
prevalence estimates. Two of the villages did not have BR data
for years 1 and 2. Thus, only the baseline and 3-year data were
considered in the analysis of this outcome.
RESULTS
Demographics and treatment coverage. The number of
subjects enrolled each year varied between 2,804 and 3,198
subjects (Table 1). In all villages, fewer males (between 37.8%
and 47.9%) were examined compared with females. Parameters such as age distribution and bed net use were very similar
between the two treatment areas. Compliance (subjects who
reported taking antiﬁlarial drugs during MDA) was assessed
during the follow-up surveys. This varied between 70.1% and
89.8% with the highest reported compliance observed in Pruda,
the area that received twice-yearly MDA (Table 2).
Prevalence and density of Mf. During the pre-MDA surveys, it became clear that the baseline prevalence in the three
study areas (Paga, Lewomada, and Pruda) was more different
than expected: Whereas Paga and Lewomada had a low unadjusted Mf prevalence of 3.9% and 5.0%, respectively; the
Mf prevalence in Pruda was 14.2% (Table 3). In Paga, the low
prevalence was relatively evenly distributed, whereas in
Lewomada, most of the area had low prevalence, but one
sub-village (Henga) with about 300 residents had a higher
prevalence of about 10%.
Following three rounds of MDA, Mf prevalence decreased to
zero in Paga and to 0.3% in Lewomada, whereas after ﬁve

semiannual rounds of MDA, the Mf prevalence in Pruda was
still 1.2% (Table 3). Logistic regression analysis of Mf results
showed that the overall effect for the semiannual treatment
regimen had 3.9 times higher odds (P < 0.001) of having Mf
compared with subjects receiving an annual dosage (Table 4).
This difference is likely driven by the higher overall prevalence
differences at baseline in the different villages (see the previous paragraph). Although there was not a signiﬁcant
treatment × time interaction, there was an overall signiﬁcant
decrease in Mf over time (P < 0.001), indicating that the odds of
Mf positivity decreased by 67% each year. Furthermore,
model-adjusted prevalence estimates indicated that the
twice-yearly treatment decreased the adjusted Mf prevalence
more rapidly through time as compared with the annual
treatment regimen (Table 5).
Analysis of Mf prevalence by age group showed similar
patterns in all three study areas with low prevalence in the
younger participants and higher prevalence in older participants (Figure 2). In all areas, reduction in Mf prevalence after
MDA was also higher in younger subjects.
The Mf prevalences at baseline in males in Paga, Lewomada, and Pruda were 4.4% (geometric mean in positives,
172 Mf/mL), 6.4% (geometric mean 517 Mf/mL), and 18.2%
(geometric mean 284 Mf/mL), respectively. Corresponding
prevalence in females were 3.6% (geometric mean 104 Mf/
mL), 3.9% (geometric mean 160 Mf/mL), and 10.7% (geometric mean 178 Mf/mL), respectively (Table 6). The gender
differences for prevalence and density were more dramatic for
participants older than 14 years. After three or ﬁve rounds of
MDA in total, only three Mf-positive adult men but 12 Mfpositive adult women were detected. This suggests that after
MDA, women of child-bearing age may still represent a reservoir for Mf.
Brugia timori and W. bancrofti coinfections. No
W. bancrofti Mf were detected at baseline or during follow-up
surveys in Paga. Furthermore, the prevalence of circulating
W. bancrofti antigen as measured by ICT was less than 1% at
baseline. Therefore, this area was considered to be not endemic
for W. bancrofti and not further tested by ICT. By contrast,
Lewomada and Pruda areas were both co-endemic for B. timori
and W. bancrofti. In Lewomada (at baseline), 36 Mf-positive
subjects were identiﬁed (5% of the total tested, including 13
children younger than 16 years): 33 were positive for B. timori
only with a geometric mean density of 290 Mf/mL, two individuals were Mf positive for B. timori (33 Mf/mL and 867 Mf/mL,
respectively) and W. bancrofti (1,383 Mf/mL and 1,067 Mf/mL,
respectively), and one individual was Mf positive for W. bancrofti
only (67 Mf/mL). All three W. bancrofti Mf-positive subjects were
also ICT positive.
Mf prevalence was highest in Pruda. Among the 146 Mfpositive subjects (14.2% of the total tested), 106 (10.3%) were

TABLE 3
Summary of prevalence of Mf, positive BR IgG4 antibody test, and circulating Wuchereria bancrofti antigen (ICT) before MDA and following 1, 2, and
3 years of initiating MDA
Paga
% Mf (CI)

Pre-MDA
Year 1
Year 2
Year 3

3.9 (3.0–5.0)
1.1 (0.6–2.0)
0.5 (0.2–1.2)
0 (0.0–0.4)

Lewomada

% BR (CI)

% ICT (CI)

12.5 (10.5–14.7)
Nd
Nd
1.8 (1.1–2.9)

Nd
Nd
Nd
Nd

% Mf (CI)

5.0 (3.6–6.8)
1.1 (0.6–2.0)
0.7 (0.3–1.5)
0.3 (0.1–1.0)

% BR (CI)

31.7 (28.3–35.2)
19.9 (17.2–22.8)
15.7 (13.4–18.3)
4.1 (2.9–5.6)

Pruda
% ICT (CI)

6.5 (4.9–8.5)
1.5 (0.8–2.5)
1.5 (0.8–2.5)
0.8 (0.4–1.7)

% Mf (CI)

% BR (CI)

% ICT (CI)

14.2 (12.2–16.5)
3.8 (2.7–5.1)
1.4 (0.9–2.4)
1.2 (0.7–2.0)

28.9 (25.7–32.3)
Nd
Nd
3.6 (2.6–5.0)

22.9 (20.4–25.5)
9.1 (7.4–11.0)
10.2 (8.5–12.3)
7.0 (5.6–8.8)

BR = Brugia Rapid; CI = 95% conﬁdence interval; MDA = mass drug administration; Mf = microﬁlariae; Nd = not determined. Paga and Lewomada received annual MDA (three rounds), whereas
Pruda received semiannual MDA (ﬁve rounds).

339

MASS DRUG ADMINISTRATION REGIMENS FOR LYMPHATIC FILARIASIS

TABLE 4
Logistic regression analysis of major infection parameter outcome
Outcome

Variable

Group

Adjusted odds ratio (95% conﬁdence interval)

P-value

Microﬁlariae

Treatment
Visit
Treatment

ICT antigen*

Visit
Treatment

1.0
3.92 (1.98, 7.78)
0.33 (0.28, 0.39)
1.0
1.49 (0.67, 3.31)
0.08 (0.06, 0.11)
1.0
14.24 (6.2, 32.69)
0.45 (0.35, 0.58)
0.62 (0.56, 0.69)

< 0.001

Brugia Rapid

1 Dose/year
2 Doses/year
NA
1 Dose/year
2 Doses/year
NA
1 Dose/year
2 Doses/year
Slope 1 dose/year
Slope 2 doses/year

Visit

< 0.001
0.31
< 0.001
< 0.001
< 0.001
< 0.001

Outcome was adjusted for potential correlation among subjects within a neighborhood. Neighborhood (village) was treated as a random effect for all villages.
* The Treatment × visit interaction effect for this outcome was signiﬁcant (P = 0.016), and the odds ratios of the slopes for annual and semiannual treatment are reported to facilitate interpretation.

B. timori Mf positive and 89 (8.6%) were W. bancrofti Mf
positive. Among the W. bancrofti Mf positives, 87 (97.8%)
were also ICT positive. Based on the prevalence of single infections and under the assumption of independent transmission, it was calculated that prevalence of coinfections
should be about 0.09%. Interestingly, the number of Mfpositive coinfections was 49 (4.8% of the total number of
participants tested) and much higher than expected (Table 7).
Because of this fairly even distribution of both ﬁlarial infections, we were able to assess the effect of MDA on both
species in the same study area. The Mf prevalence of B. timori
only, W. bancrofti only, and coinfections in this area decreased
from 5.6%, 3.9%, and 4.8% at baseline to 1.0%, 0.2%, and
0% after ﬁve rounds of MDA, respectively (Table 7).
Prevalence of positive Brugia Rapid antibody tests. The
unadjusted prevalence of ﬁlaria-speciﬁc IgG4 antibodies as
assessed by the BR test was 12.5% at baseline in the onceyearly treatment areas Paga and Lewomada and 41.7%
in Pruda (Table 3). At the reexamination 3 years after the ﬁrst
round of MDA, BR prevalence decreased signiﬁcantly to 1.8%
and 4.1% in the annual and semiannual treatment areas, respectively. Logistic regression analysis showed no signiﬁcant
difference between changes in BR prevalence by treatment
area (Table 4). BR prevalence decreased by 90% over 3 years
in both areas (Table 4).
Analysis of BR antibody prevalence in the annual MDA villages by age shows that almost no children and young adults
aged 20 years and younger were positive in Paga, whereas
more children and young adults were positive in Lewomada
(Figure 3A and B). Although the Mf prevalence was highest in
Pruda, it was a B. timori/W. bancrofti mixed infection area, and
the baseline BR prevalence was only 28.9% (lower than in
Lewomada). The BR prevalence decreased to 3.6% in year 3
(Table 3). As in Lewomada, few children and young adults

were BR positive in year 3. These results show that in all villages, the BR prevalence decreased signiﬁcantly in all age
groups after MDA (Figure 3A–C). Thus, BR prevalence decreased relatively quickly in response to MDA following the
clearance of Mf.
ICT antigen test results. Wuchereria bancrofti Mf-positive
individuals were only detected in Lewomada and Pruda.
Baseline ICT antigen prevalences for these areas were 6.5%
and 22.9%, respectively. After three rounds of MDA in Lewomada and ﬁve rounds of MDA in Pruda, ICT prevalences
decreased to 0.8% and 7.0%, respectively (Table 3). The decrease in antigen prevalence in Lewomada with a low baseline
antigen prevalence was more rapid than that in Pruda where
the baseline prevalence was high. Logistic regression analysis
of the posttreatment ICT results showed that the semiannual
treatment had higher odds of ICT positivity as compared with
the annual treatment group. The interaction was signiﬁcant
and the slope estimates indicated that the annual treatment
group had a stronger decline through time when compared
with the semiannual treatment group (Table 4). However,
model-adjusted prevalence estimates revealed that there is a
stronger decline between baseline and 3-year in the semiannual treatment group (20.9% at baseline to 6% at 3 years)
as compared with the annual treatment group (1.8% at
baseline to 0.17% at 3 years) (Table 5). Analysis of results
from both Mf and ICT outcomes suggests that interpretation
of effects on the odds scale masks the more rapid changes in
prevalence through time for the semiannual treatment group
that is evident in the unadjusted and adjusted prevalence
estimates.
Analysis of ICT antigen prevalence by age group is consistent with this ﬁnding (Figure 4). It appears that W. bancrofti
antigen is cleared faster in persons with light infections (in low
prevalence areas or in younger subjects).

TABLE 5
Model predictions (adjusted prevalence) of major infection parameter outcome for annual (1 dose/year) and semiannual (2 doses/year) mass drug
administration
Model-adjusted prevalence and 95% conﬁdence interval
Treatment regimen

Round

Mf

BR

ICT

1 Dose/year
2 Doses/year
1 Dose/year
2 Doses/year
1 Dose/year
2 Doses/year
1 Dose/year
2 Doses/year

Baseline
Baseline
1 year
1 year
2 year
2 year
3 year
3 year

3.39 (2.12, 5.37)
12.09 (7.57, 18.75)
1.16 (0.73, 1.83)
4.39 (2.7, 7.05)
0.39 (0.24, 0.64)
1.51 (0.89, 2.53)
0.13 (0.07, 0.23)
0.51 (0.28, 0.92)

19.8 (12.77, 29.4)
26.91 (16.45, 40.77)
ND
ND
ND
ND
2.04 (1.22, 3.4)
3.02 (1.63, 5.52)

1.83 (1, 3.32)
20.94 (13.09, 31.78)
0.83 (0.46, 1.47)
14.18 (8.67, 22.34)
0.37 (0.2, 0.71)
9.35 (5.58, 15.25)
0.17 (0.08, 0.37)
6.04 (3.5, 10.24)

Outcome was adjusted for potential correlation among subjects within a neighborhood. Neighborhood (Village) was treated as a random effect for all villages.

Mf = microﬁlariae.

Pruda

Lewomada

All

> 15

£ 15

All

> 15

£ 15

All

> 15

£ 15

Age (years)

Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female
Male
Female

Gender

Indonesia has a 50-year history of local LF control using
village-based low-dose DEC distribution. A classic example
was the sustainable control of B. timori in a single village in
Flores Island.8,9 Unfortunately, elimination of LF was not the
goal of this intervention, efforts were restricted to relatively
small geographic areas, and the fear of adverse events, especially in areas with brugian ﬁlariasis, hindered the expansion
of the efforts. After clinical trials indicated that DEC combined
with ALB was safe and efﬁcacious for LF caused by
B. timori,10,11 Indonesia joined the GPELF in 2002 and
implemented the WHO recommended MDA strategy using

Village

DISCUSSION

Paga

289
308
239
555
528
863
144
141
167
270
311
411
200
174
284
369
484
543

N

FIGURE 2. Microﬁlariae (Mf) prevalence in the study villages Paga
(A), Lewomada (B), and Pruda (C) by age group, at baseline and followup 1, 2, and 3 years following initiation of mass drug administration
(MDA). Paga and Lewomada received three rounds of MDA after the
baseline survey and at 12 and 24 months, whereas Pruda received ﬁve
rounds of MDA with additional rounds at 6 and 18 months. This ﬁgure
appears in color at www.ajtmh.org.
4 (1.4)
5 (1.6)
19 (7.9)
26 (4.7)
23 (4.4)
31 (3.6)
7 (4.9)
6 (4.3)
13 (7.8)
10 (3.7)
20 (6.4)
16 (3.9)
17 (8.5)
11 (6.3)
71 (25.0)
47 (12.7)
88 (18.2)
58 (10.7)

Mf+ (n, %)

Baseline

301
132
153
99
172
104
374
229
615
128
517
160
151
164
330
181
284
178

Geomean (Mf/mL)

N

220
251
172
351
392
602
175
170
185
316
360
486
207
192
261
322
468
514

0 (0)
0 (0)
9 (5.2)
2 (0.6)
9 (2.3)
2 (0.3)
2 (1.1)
0 (0)
6 (3.2)
1 (0.3)
8 (2.2)
1 (0.2)
1 (0.5)
2 (1.0)
20 (7.7)
14 (4.3)
21 (4.5)
16 (3.1)

Mf+ (n, %)

Year 1

0
0
103
171
103
171
82
0
52
50
58
50
6,383
47
232
77
271
73

Geomean (Mf/mL)

N

248
294
178
394
426
688
174
177
203
299
382
476
200
194
300
349
500
543

0 (0)
0 (0)
2 (1.1)
4 (1.0)
2 (0.5)
4 (0.6)
0 (0)
0 (0)
5 (2.4)
1 (0.3)
5 (1.3)
1 (0.2)
1 (0.5)
1 (0.5)
6 (2.0)
7 (2.0)
7 (1.4)
8 (1.5)

Mf+ (n, %)

Year 2

0
0
240
95
240
95
0
0
93
50
93
50
350
183
84
121
103
127

Geomean (Mf/mL)

TABLE 6
Comparison of the Mf prevalence and density in infected male and female subjects by village and year
N

197
232
160
313
357
545
174
168
224
303
398
471
203
195
234
395
437
590

0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)
1 (0.4)
2 (0.7)
1 (0.3)
2 (0.4)
0 (0)
0 (0)
2 (0.9)
10 (2.5)
2 (0.5)
10 (1.7)

Mf+ (n, %)

Year 3

0
0
0
0
0
0
0
0
17
306
17
306
0
0
33
51
33
51

Geomean (Mf/mL)
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TABLE 7
The change of Mf prevalence and density over time in single and in mixed infection of Brugia timori and Wuchereria bancrofti in Pruda, the twiceyearly treated village
B. timori
N

Pre-mass drug
administration
Year 1
Year 2
Year 3

n

Mf+ (%, CI)

W. bancrofti
Geomean (Mf/mL)

n

Mf+ (%, CI)

B. timori + W. bancrofti
Geomean (Mf/mL)

1,027

57

5.6 (4.3–7.1)

114 (77–167)

40

3.9 (2.9–5.3)

148 (97–227)

982
1,042
1,027

10
5
10

1.0 (0.5–1.9)
0.5 (0.2–1.1)
1.0 (0.5–1.8)

200 (40–1,008)
120 (23–632)
54 (25–119)

23
6
2

2.3 (1.6–3.5)
0.6 (0.3–1.2)
0.2 (0.05–0.7)

105 (64–170)
102 (23–453)
24 (0.3–1,927)

n

Mf+ (%, CI)

Geomean B. timori (Mf/mL)

Geomean W. bancrofti (Mf/mL)

49

4.8 (3.6–6.2)

401 (251 –641 )

163 (106–249)

4
3
0

0.4 (0.2–1.0)
0.3 (0.1–0.8)
0 (0.0–0.4)

297 (83–1,070)
82 (7–1,045)
Nd

157 (9–2,645)
126 (18–871)
Nd

CI = conﬁdence interval; Mf = microﬁlariae.

annual administration of this drug combination.12 In the present study, we compared the effect of three annual rounds or
ﬁve semiannual rounds of MDA using DEC combined with ALB
on LF caused by B. timori and W. bancrofti in Flores Island,
Indonesia. Reported compliance rates were above 65% in all
study areas, and it appears that semiannual MDA did not
signiﬁcantly increase the cumulative compliance as reported
by study participants.
The baseline LF prevalences in the study areas were lower in
areas that received three rounds of annual MDA, whereas the
higher prevalence area received ﬁve rounds of semiannual
MDA. In the two areas that received annual MDA, both the
unadjusted and adjusted Mf prevalence decreased after two
rounds of MDA to below 1%. This threshold indicates in preTAS that the area is eligible for TAS.13 In the area with higher
baseline prevalence (Pruda), the unadjusted prevalence still
exceeded this threshold after ﬁve semi-annual rounds of MDA,
suggesting that additional rounds are needed. These results
indicate that baseline Mf prevalence may be a more important
determinant for whether an area is ready for TAS than the
number of rounds or frequency of MDA alone. Many studies
have shown that high compliance is a key factor for a successful
MDA program.6,14 Low prevalence areas with good compliance
may be eligible for TAS even after a couple of rounds, whereas
some high prevalence areas may need more than ﬁve rounds of
semiannual MDA despite good compliance.
At baseline, we observed higher Mf prevalence in males
compared with females, especially in adults older than 15 years,
and this subpopulation should be speciﬁcally addressed during
social mobilization in early stages of MDA programs. Higher Mf
prevalence in men is often seen in LF.15 Interestingly, at the end
of the MDA program, most remaining Mf-positive subjects were
women older than 15 years. Therefore, it may be helpful to
speciﬁcally target adult women in eastern Indonesia in later
stages of LF elimination programs. Previous studies in eastern
Indonesia on the knowledge, attitudes, and practices concerning LF have indicated that factors that inﬂuence compliance change over the course of an LF MDA program, and social
mobilization campaigns may have to be speciﬁcally tailored to
changing target groups.16
Differences in baseline prevalence make it difﬁcult to compare the impact of annual and semiannual MDA in the present
study. Computer modeling studies using assumptions for
W. bancrofti infections from Ghana and India predicted that
twice-yearly MDA would reduce the duration of MDA programs in half and reduce the overall program costs.6 Although
this may be true in some settings, our data from Flores are not
consistent with these predictions. It appears that annual MDA
with DEC and ALB can be highly effective in areas with low to
moderate Mf prevalence, and high compliance may be more
important than the frequency of MDA rounds.

Whereas the Paga area was endemic for B. timori alone, the
other two areas were co-endemic for B. timori and
W. bancrofti. The prevalence of circulating W. bancrofti antigenemia in Lewomada was 6.5%, but only three W. bancrofti
Mf-positive individuals were detected at baseline. Therefore,
we focused our comparison of the effects of MDA on the two
infections on the data from Pruda, which had high baseline
prevalences for both infections. Our results showed clearly
that at baseline, coinfections with B. timori and W. bancrofti
were more common than expected. Both ﬁlarial species are
transmitted by anopheline mosquitos, but by different vector
species. On Alor Island, for example, B. timori is transmitted by
Anopheles barbirostris, whereas W. bancrofti is transmitted by
Anopheles subpictus.15 The high prevalence of coinfection
suggests that the same people may be heavily exposed to
bites from both vector mosquito species. Furthermore, it appears that both ﬁlarial species responded well to MDA; because the prevalence of B. timori was higher than that of
W. bancrofti at baseline, the residual prevalence of B. timori
was also slightly higher after ﬁve rounds of MDA.
In the absence of a reliable antigen test for brugian ﬁlariasis,
the BR test has been recommended for mapping and monitoring and evaluation of LF elimination programs in Brugiaendemic areas.13 Previous studies have shown that this
antibody test is sensitive for both B. malayi and B. timori infections17 and that BR prevalences decrease following MDA.5
However, the present study demonstrates that BR prevalences decreased rapidly after MDA in three different areas: in
the low prevalence area (Paga), the prevalence decreased
over 36 months to 14.4% of the baseline prevalence and in the
higher prevalence areas, it decreased to 12.9% (Lewomada)
and 12.5% (Pruda) of the baseline values. Furthermore, the
analysis by age group showed that the decline was seen in all
age groups and was not limited to children and young adults.
The posttreatment decrease in BR antibody prevalence is
faster than that reported from W. bancrofti infections for antibodies reactive to the ﬁlarial antigen Bm14.18 This may be
related to a special property of recombinant BmR1 antigen
used in the test and to the diagnostic platform. In previous
studies, antibodies reactive with Bm14 antigen were detected
by ELISA, whereas the point-of-care BR test used in the present study detects antibodies reactive with BmR1 antigen by
paper immunochromatography. IgG4 antibodies reactive with
the BmR1 antigen may decrease quickly below the detection
threshold of BR, but this does not necessarily mean that
antiﬁlarial antibodies reactive with the BmR1 antigen have
been totally cleared.
The areas Lewomada and Pruda were co-endemic for
W. bancrofti, and circulating antigen prevalences were
assessed by ICT. ICT prevalences decreased over 36 months to
12.3% and 30.6% of the baseline in these two treatment areas,
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FIGURE 4. Prevalence of positive ICT antigen tests for Wuchereria
bancrofti in the study villages Lewomada (A) and Pruda (B) by age
group, at baseline and follow-up 1, 2, and 3 years following initiation of
mass drug administration (MDA). Lewomada received three rounds of
MDA after the baseline survey and at 12 and 24 months, whereas
Pruda received ﬁve rounds of MDA with additional rounds at 6 and 18
months. This ﬁgure appears in color at www.ajtmh.org.

FIGURE 3. Prevalence of positive Brugia Rapid (BR) antibody tests
in the study villages Paga (A), Lewomada (B), and Pruda (C) by age
group at baseline and 3 years following initiation of mass drug administration (MDA). In addition, in Lewomada Brugia Rapid tests were
also performed in year 1 and 2 after the start of MDA. Paga and
Lewomada received three rounds of MDA after the baseline survey
and at 12 and 24 months, whereas Pruda received ﬁve rounds of MDA
with additional rounds at 6 and 18 months. This ﬁgure appears in color
at www.ajtmh.org.

respectively. The more rapid decrease in Lewomada may be
related to the relatively low prevalence and intensity of infection
in that treatment area. Decreases in ICT prevalence following
MDA have been reported many times before, and it is well
known that circulating antigen levels decrease a few months
after successful treatment.19,20 The ﬁnding that BR prevalence
decreased more rapidly than ICT in Pruda (co-endemic for
B. timori and W. bancrofti) is an interesting new ﬁnding.
In conclusion, our study did not detect an obvious advantage of twice-yearly MDA in areas that were co-endemic for
B. timori and W. bancrofti. However, differences in baseline

infection prevalence in this study may have obscured the
potential superiority of semiannual MDA. The study showed
that three rounds of once-yearly MDA with fairly high compliance reduced Mf prevalence to below 1% in low-endemicity
areas. High compliance with annual MDA may be sufﬁcient to
eliminate LF in most settings, and compliance is probably
more important than the frequency of MDA. Our results also
suggest that the BR antibody test is a good marker for successful MDA in areas with brugian ﬁlariasis.
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